Page 25 - 78_04
P. 25
M.
C.
AVENDAÑO
7.
Yao,
F.;
MacKenzie,
R.
G.,
(2010)
“Obesity
Drug
Update:
The
Lost
Decade?”
Pharmaceuticals,
3,
3494--3521.
8.
Nören--Müller,
A.;
Reis--Corrêa,
I.;
Prinz,
H.;
Rosenbaum,
C.;
Saxena,
K.;
Schwalbe,
H.
J.;
Vestweber,
D.;
Cagna,
G.;
Schunk,
S.;
Schwarz,
O.;
Schiewe,
H.;
Waldmann,
H.,
(2006)
“Discovery
of
protein
phosphatase
inhibitor
classes
by
biology--oriented
síntesis”,
Proc.
Natl.
Acad.
Sci.
U
S
A.,
103,10606--10611.
9.
Lachance,
H.;
Wetzel,
S.;
Kumar,
K.;
Waldmann,
H.,
(2012)
“Charting,
Navigating,
and
Populating
Natural
Product
Chemical
Space
for
Drug
Discovery”,
J.
Med.
Chem.,
55,
5989--6001.
10.
Vasilevich,
N.
I.;
Kombarov,
R.
V.;
Genis,
D.
V.;
Kirpichenok,
M.
A.,
(2012)
“Lessons
from
Natural
Products
Chemistry
Can
Offer
Novel
Approaches
for
Synthetic
Chemistry
in
Drug
Discovery”,
J.
Med.
Chem.,
55,
7003--7009.
11.
Schreiber,
S.
L.,
(2000)
“Target--oriented
and
diversity--oriented
organic
synthesis
in
drug
discovery”,
Science,
287,
1964--1969.
12.
Nielsen,
T.
E.;
Schreiber,
S.
L.,
(2008)
“Towards
the
Optimal
Screening
Collection:
A
Synthesis
Strategy”,
Angew.
Chem.
Int.
Ed.
Engl.,
47,
48--56.
13.
Baniecki,
M.
L.;
Wirth,
D.
F.;
Clardy,
J.,
(2007)
“High--throughput
Plasmodium
falciparum
growth
assay
for
malaria
drug
discovery”,
Antimicrob.
Agents
Chemother.,
51,
716--723.
424
